Navigation Links
ChemGenex's omacetaxine may provide first viable treatment option for highly resistant form of CML
Date:6/1/2009

MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 1st, 2009) ChemGenex Pharmaceuticals Limited (ChemGenex) (ASX:CXS) announced that the latest data from its pivotal study of omacetaxine in patients with T315I-positive chronic myeloid leukemia (CML) was the subject of an oral presentation and discussion today at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The open label Phase 2/3 study (CGX-635-CML-202) investigated the use of omacetaxine, administered subcutaneously in CML patients who had failed imatinib and who have the highly drug resistant T315I kinase domain mutation.

Dr. Jorge Cortes, MD, Professor of Medicine and Deputy Chair in the Department of Leukemia at The University of Texas, MD Anderson Cancer Center, a lead investigator in the study, presented the data. Dr. Cortes said, "It appears that omacetaxine was well tolerated in this study and durable hematological and cytogenetic responses were observed in some CML patients with the T315I mutation." He added that "Several novel drugs have already been investigated in this difficult-to-treat population, but they have not had a reasonable risk:benefit ratio. These results suggest that omacetaxine may represent the first viable treatment option for this population of patients who currently have no established treatment options."

Data were presented from 66 patients: 40 in chronic phase, 16 in accelerated phase and 10 in blast phase. Highlights of the data were:

Chronic phase patients

  • Complete hematologic response (CHR) rate of 85% with a median response duration 8.9 months
  • Major cytogenetic response (MCyR) rate of 15% with a median response duration 6.1 months

Accelerated phase patients

  • CHR rate of 31% with a median duration 4.1 months
  • MCyR rate of 6% with a median response duration 1.8 months

Blast phase patients

  • CHR rate of 20% with a median duration 3.3 months

Tolerability

Investigators reported that omacetaxine is generally well tolerated, and that the most common side effect is reversible and transient myelosuppression.

Commenting on the presentation, Dr. Greg Collier, Chief Executive Officer and Managing Director of ChemGenex, said, "This is a very important milestone in the development of omacetaxine and in the evolution of ChemGenex. The data presented today will be provided to the FDA in the final part of our rolling NDA submission; this project remains on target for completion in Q3 this year." Dr. Collier finished by expressing his deep appreciation for patients and investigators who participated in this important trial.

Dr. Collier and ChemGenex's Chief Medical Officer Dr. Adam Craig will host an investor conference call and webcast to discuss the clinical results from both ASCO and the EHA Congress on Thursday 11th of June at 10 am AEST. Details of this event will be advised in coming days.

Omacetaxine Overview

Omacetaxine mepesuccinate is a first-in-class cetaxine with demonstrated clinical activity as a single agent in a range of hematological malignancies. Omacetaxine has a novel mechanism of action, specifically binding to the ribosomal A-site cleft and inhibiting protein translation of short-lived oncoproteins that are upregulated in leukemic cells (particularly Cyclin-D1, Mcl-1 and c-Myc). As omacetaxine acts independently of tyrosine kinase inhibitors, it may have a therapeutic advantage for patients who have developed resistance to TKIs. Omacetaxine is administered subcutaneously.


'/>"/>

Contact: Joan Kureczka
Joan@kureczka-martin.com
415-821-2413
Kureczka/Martin Associates
Source:Eurekalert

Related medicine news :

1. Study provides hope that some transplant patients could live free of antirejection drugs
2. Study provides hope that some transplant patients could live free of anti-rejection drugs
3. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
4. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
5. USAID Provides Additional Wildfire Assistance to Greece
6. MinuteClinic Becomes Participating Provider with Assurant Health
7. Over 500,000 Health Care Providers Now Cutting Costs, Saving Time Through CAQH Administrative Simplification Initiative
8. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
9. New knock-out gene model provides molecular clues to breast cancer
10. Area Health Care Providers Announce Plans to Integrate Services
11. Crdentia Selected by High Rock Raceway to Provide Healthcare Staffing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... scale; from third world countries to hospitals in the United States, it’s a ... conversation on the current obstacles facing infection prevention and offers strategies for the ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) ... at 9618 Huebner Road. The clinic is the group’s 7th location in San Antonio ... Ali Higgins, PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just two days, ... vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times ... 2,000 consumers (and counting) already backing the campaign. , “We are very ...
(Date:3/24/2017)... ... ... The law firm of Enea, Scanlan & Sirignano, LLP, with ... C. Enea has joined the firm as an associate attorney. Ms. Enea, who previously ... law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha A. Lyons, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner ... in Frederick, MD. Judy says, “I am passionate about sharing Reiki as a ... very difficult and challenging time.” , A Certified Medical Reiki™ Master trained by ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... cannabis products around the world are projected to gain popularity. A report ... will reach a value of USD 55.8 billion by 2025. ... industry. By the end of 2016, 28 states have now laws and ... states like Arkansas and North Dakota ...
(Date:3/24/2017)... , March 24, 2017 A ReportsnReports.com report ... been growing rapidly as the global sales of Adcetris and Kadcyla ... in the antibody drug conjugates market is driven by large number ... and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology: